We are developing a range of donor-derived (allogeneic) virus-specific T cell therapies to manage infectious complications in patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT).
About 15,0001 allo-HSCT procedures are conducted in Europe each year and an additional 8,0002 in the United States. In patients who have received HSCT, there are variable levels of post-transplant immune deficiency while the transplanted hematopoietic stem cells slowly generate new immune cells.
During this period HSCT patients are susceptible to infection from viruses and other microbes. Viruses that are particularly problematic include CMV (cytomegalovirus) and ADV (adenovirus).
In response, we are developing the Cytovir and RapX product portfolios with Cytovir CMV being commercially available in selected countries in Europe. These product portfolios consist of patient-specific cellular immunotherapies derived from naturally occurring donor T cells which may accelerate antigen-specific immune reconstitution following HSCT3.